Horizon Increases Offer For Depomed | Chemical & Engineering News
Volume 93 Issue 30 | p. 28 | Concentrates
Issue Date: July 27, 2015

Horizon Increases Offer For Depomed

Department: Business
Keywords: pharmaceuticals, acquisition, stock offer, takeover

Ireland’s Horizon Pharma has increased its unsolicited, all-stock offer to acquire pain and neurology drugmaker Depomed by 13%. Now at $33.00 per share, a deal would be worth about $2 billion. The offer is contingent on California-based Depomed entering into discussions with Horizon, a specialty and orphan drug firm. Depomed has already rejected previous offers and points out that the most recent one does not increase the amount of Horizon stock that Depomed shareholders would receive or their ownership stake but only reflects a recent rise in Horizon’s stock price.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment